Loading provider…
Loading provider…
Hematology & Oncology Physician in New Haven, CT
NPI: 1407021140Primary Practice Location
YALE-NEW HAVEN HOSPITAL
35 Park St, New Haven, CT
Primary Employer
Yale Medicine
yalemedicine.org
HQ Phone
Get M.D. Iris's Phone NumberMobile
Get M.D. Iris's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCT State Medical License
Yale University
fellowship • Hematology and Medical Oncology
2008 - 2011
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 96 | 164 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 87 | 229 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 21 | 65 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 18 | 105 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 15 | 15 |
Authors: Stuart Seropian, Lohith Gowda, Jan Philipp Bewersdorf, Amer Zeidan, Nikolai Podoltsev
Journal: Leuk Lymphoma
Publication Date: 2020-05-02
Authors: Ian Flinn, Ranjana Advani, Jason Kaplan, Michael Pourdehnad, Vaishalee Kenkre, Julio Chavez
Journal: EJHaem
Publication Date: 2022-01-14
Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant.
Authors: Stuart Seropian, Alfredo Axtmayer, Lohith Gowda, Shalin Kothari, Francine Foss, Stephanie Halene
Journal: PLoS One
Publication Date: 2025-04-28
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Lenalidomide, BIOLOGICAL: Blinatumomab
Lead Sponsor: Marker Therapeutics, Inc.
Intervention / Treatment: DRUG: MT-401
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT), DRUG: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy